Obermatt
See Similar Stocks →

Samsung Epis

KSC:0126Z0 · KR70126Z0002
BiotechnologySmall

360

20
EV / EBIT39
Price / Owner Earnings30
Owner Earnings Yield98
Dividend Yield1
Price/Sales19
EV / Gross Profit42
Price/Book67
Returns on capital82
EBIT Margin32
Gross Profitability37
Cash Conversion1
Owner Earnings Margin98
Sales growth50
Profit growth79
Reinvestment33
Price momentum50
Debt load81
Refinancing65
Debt Payback44
Liquidity4
Analyst ratings35
Opinion Changes50
Price Target Upside90
Market mood5

Profile

CountrySouth Korea
IndustryBiotechnology
SizeSmall
TypePublic Company
ExchangeKOSE
Websitesamsungepisholdings.com
ISINKR70126Z0002
Last UpdateApr 2, 2026
Indices
KOSPI (South Korea)

Description

Analysis

Middle-of-the-road

Samsung Epis Holdings Co., Ltd. is a middle-of-the-road business: neither the economics nor the price stand out from the peer group.

The price is attractive. You pay 11.3× its owner earnings: the cash an owner could take out each year, which is in the historically attractive zone.

The trajectory is moderate and the balance sheet is stretched. Analyst sentiment is cautious.

What to watch: Reported profits have run ahead of actual cash for several periods. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
19
2026

All-time high

26

Mar 2026

All-time low

19

Jun 2026

Average rank

23

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
19
—
—
—
Price/Earnings
25
—
—
—
Price/Book
67
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
23
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Samsung Epis with its peers
Innovent Biologics
HKG:1801
68
CountryChina
IndustryBiotechnology
SizeLarge
Full Stock Analysis →
Telix Pharmaceuticals
ASX:TLX
30
CountryAustralia
IndustryBiotechnology
SizeMedium
Full Stock Analysis →
Pharmicell
KSC:005690
35
CountrySouth Korea
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Ascentage Pharma Group
HKG:6855
26
CountryChina
IndustryBiotechnology
SizeMedium
Full Stock Analysis →
Mesoblast
ASX:MSB
42
CountryAustralia
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
CSL
ASX:CSL
40
CountryAustralia
IndustryBiotechnology
SizeX-Large
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →